EUVIMEDEUVIMED entdecken
Crossref

Safety and short-term efficacy of mirabegron in children with valve bladder: a pilot study

Ramesh Babu, Thiyagarajan Chittibabu, Sugandh Chadha

Pediatric Surgery International · 2022-03 · 38 (3) · 493-498

DOI: 10.1007/s00383-021-05040-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Surgery International, online erschienen am 02.12.2021. Verfasst von Ramesh Babu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Urology, Sri Ramachandra Medical College and Research Institute, Porur, Chennai, Tamil Nadu, 600116, India. drrameshbabu1@gma…. Hauptthemen laut MEDLINE: Urinary Bladder, Urinary Bladder, Overactive. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AIMS: This pilot study aims to assess the short-term efficacy and safety of mirabegron in valve bladder, an important cause of persistent hydronephrosis after successful treatment of posterior urethral valves (PUV). METHODS: Twenty-two patients with early valve bladder (no residual PUV; persistent hydronephrosis, wetting and urodynamic evidence of detrusor overactivity) were included. Three subjective parameters: frequency, wetting episodes; patient perception of bladder condition score (PPBC) and four objective parameters: uroflow index (UI = Qave/Qmax), voided volume (VV = voided volume/ expected bladder capacity), maximum filling pressure (P det-max) and society of fetal urology (SFU) hydronephrosis grading were analysed pre- and post-3-month treatment with mirabegron (0.5-1 mg/kg/day). All patients were observed for heart rate, BP, ECG changes during therapy. RESULTS: There was significant reduction (p = 0.001) in mean frequency (pre 15; post 10), wetting episodes (pre 5; post 2) and PPBC (pre 4; post 3). There was significant improvement (p = 0.01) in mean UI (pre 0.3; post 0.5), VV (pre 0.54; post 0.72), Pdet-max (pre 42; post 25) and hydronephrosis grade (pre 3.5; post 2.2). There were no significant side effects. CONCLUSION: This pilot study establishes short-term efficacy and safety of mirabegron in valve bladder with overactivity. Further larger long-term studies are warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary BladderUrinary Bladder, OveractiveAcetanilidesChildHumansPilot ProjectsThiazolesTreatment OutcomeUrodynamics

Stichwörter der Autor:innen

Bladder overactivityHydronephrosisMirabegronValve bladder

Substanzen

AcetanilidesThiazolesmirabegron

Autor:innen und Institutionen

  • Department of Pediatric Urology, Sri Ramachandra Medical College and Research Institute, Porur, Chennai, Tamil Nadu, 600116, India. drrameshbabu1@gmail.com.
  • Department of Pediatric Urology, Sri Ramachandra Medical College and Research Institute, Porur, Chennai, Tamil Nadu, 600116, India.

Zitieren

APA

Babu, R., Chittibabu, T., & Chadha, S. (2022). Safety and short-term efficacy of mirabegron in children with valve bladder: a pilot study. Pediatric Surgery International, 38(3), 493-498. https://doi.org/10.1007/s00383-021-05040-8

Vancouver

Babu R, Chittibabu T, Chadha S. Safety and short-term efficacy of mirabegron in children with valve bladder: a pilot study. Pediatric Surgery International. 2022;38(3):493-498. doi:10.1007/s00383-021-05040-8

BibTeX
@article{Babu2022,
  author = {Babu, Ramesh and Chittibabu, Thiyagarajan and Chadha, Sugandh},
  title = {Safety and short-term efficacy of mirabegron in children with valve bladder: a pilot study},
  journal = {Pediatric Surgery International},
  year = {2022},
  volume = {38},
  number = {3},
  pages = {493--498},
  doi = {10.1007/s00383-021-05040-8}
}
Kostenlos starten →